Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

The US Food and Drug Administration (FDA) granted approval for a second treatment for metabolic dysfunction-associated ...

Some of the losses are down to pharma's broader problems: notably, President Trump's tariff and price-cut threats. But there ...